The 2021 fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System formally recognizes four spinal entities: spinal ependymoma, spinal ependymoma with MYCN amplification, spinal subependymoma, and spinal myxopapillary ependymoma. Diagnosis is no longer a matter of histology alone. Instead, clinicians must integrate the anatomical compartment, the microscopic appearance of the tumor, and its molecular signature, most often assessed through DNA methylation profiling. That shift matters because the subtypes behave very differently. Myxopapillary ependymomas, for example, were upgraded from grade 1 to grade 2 after clinicians realized that incompletely removed tumors, once watched passively, could recur with spread through the subarachnoid space, a complication that typically forces craniospinal irradiation and carries substantial morbidity.

Pediatric-specific molecular data are beginning to sharpen this picture. In the HIT-MED spinal cohort of 83 patients aged 22 or younger, methylation classes broke down as 63 percent myxopapillary, 33 percent conventional spinal ependymoma, and 4 percent MYCN-amplified. Strikingly, within this pediatric population the molecular class did not clearly separate risk levels between the two most common groups; instead, the extent of surgical resection and the WHO grade remained the dominant determinants of progression-free survival. Molecular profiling, in other words, refines biological classification, but for most children the scalpel and the microscope still tell the most important part of the story.

The exception is the MYCN-amplified subtype, which the review describes as one of the most aggressive entities in the entire ependymoma family. These tumors tend to relapse early, typically within about 2.3 years, and can prove fatal despite aggressive multimodal treatment regardless of the age at diagnosis. Identifying MYCN amplification therefore has immediate clinical consequences: high-risk counseling, intensified craniospinal surveillance, and consideration of clinical trials or novel therapeutics. The authors argue that every spinal ependymoma specimen should undergo reflex testing for MYCN amplification alongside formal WHO 2021 grading and, where available, methylation profiling. Even the ostensibly indolent myxopapillary tumors carry sobering long-term statistics, with a 10-year progression-free survival of roughly 59 percent in mixed-age datasets, and within pediatric myxopapillary disease, methylation subtype B showed a trend toward better five-year progression-free survival than subtype A, 86 percent versus 56 percent, though the difference has not reached statistical significance.

Clinically, these tumors announce themselves quietly. Adults and older children typically report progressive sensory disturbance, gait imbalance, weakness, axial back pain, or radicular pain, and most patients are still ambulatory at diagnosis. The insidious tempo, however, often means the tumor has extended over multiple spinal segments by the time imaging is obtained. In preverbal children the presentation can be maddeningly nonspecific: torticollis, regression of motor milestones, refusal to walk or crawl, or simple irritability, signs easily misattributed to musculoskeletal or developmental causes. The review stresses that any suspicion demands gadolinium-enhanced MRI of the entire neuraxis, including the brain, because drop metastases occur in a minority of patients and missing them leads to under-staging and inadequate adjuvant planning.

On imaging, the intramedullary subtypes typically show symmetric cord expansion, well-demarcated margins, contrast enhancement, polar cysts, and syringomyelia in 40 to 70 percent of cases. A rim of hemosiderin at the tumor poles, the so-called cap sign, hints at a distinct gliotic plane that surgeons can exploit for dissection. MYCN amplification itself cannot be seen radiographically, but irregular margins, infiltrative extension, multifocal nodularity, or leptomeningeal enhancement should raise suspicion for high-risk molecular disease. Myxopapillary tumors behave differently, arising extramedullary at the filum terminale with a lobulated, avidly enhancing morphology that displaces rather than infiltrates neighboring nerve roots.

Surgery sits at the center of management, and the review frames every operative decision along three fronts: whether gross total resection is anatomically feasible, what functional neurological risks it carries, and what the biological risk of recurrence or dissemination happens to be. Gross total resection is the most consistent modifiable predictor of progression-free survival, with contemporary series reporting rates of roughly 72 to 83 percent. Continuous multimodal intraoperative neuromonitoring, combining somatosensory evoked potentials, transcranial motor evoked potentials, and D-wave recording, allows real-time assessment of the dorsal columns and corticospinal tract, and a sustained deterioration in motor potentials or a significant D-wave drop strongly predicts permanent motor deficit. When signals fail irreversibly, a deliberate subtotal resection may be the wiser course, and early postoperative MRI within 24 to 48 hours guides whether a second-look operation should precede any adjuvant therapy. For myxopapillary lesions, meticulous capsule preservation is paramount, because capsular violation is associated with local recurrence, cerebrospinal fluid dissemination, and the need for radiotherapy; en bloc resection is preferred when technically feasible.

In children, the spine itself becomes a battleground. Postoperative deformity is arguably the most important surgical morbidity in this population, and the data are stark: in one series of 161 children, 27 percent eventually required fusion, with risk rising sharply in those under 13, those with preoperative scoliosis, tumor-associated syrinx, thoracolumbar junction involvement, or each additional resection. Another study found deformity in 38 percent of children before surgery and 69 percent afterward, even when laminoplasty was used throughout, underscoring that tumor biology and preoperative status drive much of the risk. Neither laminoplasty nor laminectomy reliably prevents kyphosis, and instrumented fusion, while stabilizing, permanently sacrifices motion and growth potential and can degrade the quality of the lifelong surveillance MRI these patients need. Radiation adds its own age-dependent hazard: a comprehensive PENTEC review found clinically significant scoliosis at vertebral doses as low as 15 Gy in infants under two, with rates exceeding 30 percent above 20 Gy in children aged two to six, thresholds substantially below the 45 to 59.4 Gy focal doses typically prescribed.

Adjuvant therapy follows a risk-adapted logic. After gross total resection of a grade 2 spinal ependymoma, most contemporary evidence supports surveillance without routine radiotherapy, since a clear benefit has not been consistently demonstrated. After subtotal resection or biopsy, focal conformal radiotherapy is recommended because incomplete resection consistently predicts inferior progression-free survival. Grade 3 tumors receive focal radiotherapy regardless of resection extent, and craniospinal irradiation is considered when dissemination is present or suspected. For myxopapillary tumors the role of postoperative radiotherapy remains genuinely contested, with some retrospective series, including pediatric cohorts, suggesting improved control even after complete resection, particularly with dose escalation above 50.4 Gy or when high-risk features exist, while other adult-dominant datasets support observation alone. A recent multi-institutional pediatric and young adult series of high-risk myxopapillary disease reported five-year overall survival of 100 percent and progression-free survival of 60.8 percent, but patients still relapsed outside the treated field and intracranially, arguing for vigilance beyond the radiation volume rather than dose escalation alone. Chemotherapy, meanwhile, has no established frontline role; it is reserved for recurrent or disseminated disease, clinical trials, or as a deliberate strategy to defer radiotherapy in infants, an approach validated for intracranial ependymoma but never formally studied in the spine.

The review’s most candid contribution may be its systematic accounting of what medicine does not know. Nearly every management domain, from radiotherapy dosing and timing to the value of molecular stratification beyond MYCN, rests on adult or mixed-age retrospective cohorts, and no prospective pediatric-specific data address whether current thresholds should differ for a growing child. Local recurrence remains the dominant failure pattern even after complete resection, and craniospinal dissemination can appear years later, which is why the authors recommend lifelong MRI surveillance for every patient, with intensified brain and full-neuraxis imaging for those with dissemination or high-risk subtypes. For isolated recurrences, repeat maximal safe resection remains the mainstay, followed by focal radiotherapy in radiation-naive patients, though cumulative dose tolerance to the spinal cord and the specter of radiation-induced deformity weigh heavily in children who face a far longer horizon of potential exposure. The path forward, the authors conclude, requires prospective multicenter studies, validated molecular risk models, and novel systemic therapies for the aggressive subtypes, so that the next generation of children with spinal ependymoma can be treated on evidence of their own rather than borrowed from adults.

Subject of Research: Molecular classification and management of pediatric spinal ependymoma

Article Title: Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

Article References: Price, A. M., Fredricks, N. S., Koutsouras, G., Vallejo, F. A., Bonfield, C., Pastakia, D. J., Luo, L. Y., Boop, F., Ramaswamy, V., & Dewan, M. C. (2026). Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of Neuro-Oncology, 180(1), Article 6. https://doi.org/10.1007/s11060-026-05816-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05816-9

Keywords: spinal ependymoma, pediatric neuro-oncology, MYCN amplification, myxopapillary ependymoma, WHO CNS5 classification, gross total resection, intraoperative neuromonitoring, adjuvant radiotherapy, spinal deformity, DNA methylation profiling, craniospinal irradiation, lifelong surveillance

The study, led by Ertugrul Senturk and Petek Erpolat of Gazi University Faculty of Medicine in Ankara, was designed to address a persistent evidence gap. Spinal ependymomas account for a substantial share of intramedullary spinal cord tumors in adults, yet no randomized trial has ever defined the optimal adjuvant strategy, and guidelines from the European Association of Neuro-Oncology acknowledge that recommendations for radiotherapy after subtotal resection rest on limited retrospective data. The TROD investigators restricted their analysis to adults aged 18 or older with histologically confirmed World Health Organization Grade 2 or Grade 3 tumors, excluding Grade 1 lesions such as myxopapillary ependymomas and any patient whose radiotherapy began more than six months after surgery, in order to create a analytically coherent cohort in which the timing question could be examined cleanly.

The methodological backbone of the study was conventional but rigorous. Clinical outcomes were estimated with Kaplan-Meier survival analysis, and prognostic factors were tested in multivariate Cox regression models, allowing the investigators to separate the independent contribution of each variable from the confounding influence of the others. Endpoints included local control, disease-free survival, progression-free survival, and overall survival, with local failure defined according to modern neuro-oncology response assessment criteria. With a median follow-up of 7.9 years in the Grade 2 cohort, the dataset offers something genuinely rare in this disease: a decade-scale view of what happens after adjuvant irradiation.

The dominant message from the Grade 2 cohort, which comprised 37 of the 45 patients, is that the extent of surgical resection remains the primary determinant of disease control. Gross total resection was achieved in 43.2 percent of these patients, and the results in that group were extraordinary: not a single local failure occurred, translating into 100 percent ten-year local control and disease-free survival. Among patients whose tumors were only subtotally resected, by contrast, 41.2 percent eventually experienced local failure, with five- and ten-year disease-free survival of 63.9 percent and 54.7 percent respectively, a difference that reached statistical significance at p = 0.006. In other words, even in an era when adjuvant radiotherapy is available, nothing the radiation oncologist delivers fully substitutes for a complete surgical excision when it can be achieved safely.

Yet the story is not simply one of surgery versus radiation. Despite the dramatic difference in local control, overall survival was statistically indistinguishable between the two resection groups, with ten-year overall survival of 88.9 percent after gross total resection versus 74.3 percent after subtotal resection, a difference that failed to reach significance at p = 0.70. This divergence between local control and survival underscores a clinical reality familiar to neuro-oncologists: spinal ependymomas often recur locally and slowly, and salvage treatment can extend life even when the initial disease control is imperfect. It also suggests that adjuvant radiotherapy, delivered to patients with residual disease, does meaningful work in suppressing local regrowth even if the ultimate survival benefit is harder to demonstrate in a cohort of this size.

The most consequential finding, however, concerns timing. Among non-GTR patients who had no evidence of tumor dissemination at the start, a surgery-to-radiotherapy interval exceeding 1.5 months emerged as the sole independent predictor of early recurrence, with the enormous hazard ratios noted above reaching significance at p = 0.04 for both disease-free and progression-free survival. The authors conclude that early adjuvant radiotherapy, ideally initiated within about six weeks of surgery, should be regarded as a critical management strategy for patients with residual Grade 2 disease. Because this was a retrospective analysis, the result cannot prove causation in the way a randomized trial could, and patients referred late for radiotherapy may differ in ways the models cannot fully capture. Even so, a signal this strong, in the largest direction imaginable, gives treating physicians a concrete, actionable benchmark in a field that has operated largely on intuition.

The study also clarified which patients face the steepest odds regardless of treatment. Younger age at diagnosis and the presence of baseline spinal dissemination were both independent adverse prognostic factors for progression and mortality. For patients who presented with spinal dissemination at the outset, the progression rate reached 60 percent and median overall survival collapsed to just 15.2 months, a sobering figure that illustrates how quickly this disease can shift from an indolent, surgically manageable problem to a disseminated, life-threatening one. These findings argue for careful baseline neuraxis imaging and heightened surveillance in any patient whose tumor has already seeded the cerebrospinal fluid pathways.

Grade 3, or anaplastic, ependymomas behaved very differently. In this small subgroup, five-year local control, progression-free survival, and overall survival were 56.3 percent, 41.7 percent, and 75.0 percent respectively, and 62.5 percent of patients progressed. Interestingly, gross total resection did achieve complete local control even in these aggressive tumors, but distant metastasis remained the dominant pattern of failure, occurring in 60 percent of progressive cases. This dissociation between local and distant control carries an important implication: for anaplastic tumors, excellent local therapy is not enough, and the field may need to think in terms of systemic or craniospinal strategies to address the risk of dissemination, an area where current evidence remains thin and clinical trials are urgently needed.

The technical details of the radiation itself matter as well, even though the published abstract centers on timing and extent of resection. Modern practices, including image-guided and increasingly stereotactic approaches to the spine, allow high conformal doses to be delivered to residual tumor while sparing the exquisitely radiation-sensitive spinal cord, and the study’s data collection aligned with standard toxicity grading frameworks to capture treatment-related harm. The authors report no funding sources and no competing interests, and the dataset is available from the corresponding author upon reasonable request, inviting external validation of their findings.

What should patients and clinicians take away from this work? First, gross total resection remains the gold standard, and every effort should be made to achieve it when it can be done without unacceptable neurological risk, an aim increasingly supported by intraoperative neuromonitoring. Second, when residual disease is left behind, adjuvant radiotherapy demonstrably provides effective local control in Grade 2 tumors, and delaying it beyond roughly six weeks appears to carry a substantial and measurable cost in recurrence risk. Third, Grade 3 histology and initial spinal dissemination mark patients for intensified surveillance and, plausibly, for future trials of more aggressive combined-modality therapy. In a rare disease where no single institution will ever accumulate enough patients to answer these questions alone, the multicenter TROD model itself deserves credit: by pooling nearly three decades of experience across ten centers, the group has produced one of the clearest evidence-based guides yet for a treatment dilemma that neurosurgeons and radiation oncologists confront every week.

Subject of Research: Long-term outcomes of adjuvant radiotherapy in adult WHO Grade 2 and 3 spinal ependymomas

Article Title: Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005)

Article References: Senturk, E., Erpolat, P., Kamer, S., Yücel, B., Barış, B. Ş., Bayatfard, P., Atasoy, B., Çetinayak, H. O., Atasever Akkaş, E., Baltalarlı, P. B., & Delikgöz Soykut, E. (2026). Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005). Journal of Neuro-Oncology, 179(2), Article 77. https://doi.org/10.1007/s11060-026-05793-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05793-z

Keywords: spinal ependymoma, adjuvant radiotherapy, gross total resection, subtotal resection, local control, disease-free survival, progression-free survival, overall survival, anaplastic ependymoma, spinal dissemination, recurrence timing, neuro-oncology